南洋行家论股
IHH医疗保健 须消除外汇冲击
目标价：7.00令吉
最新进展：
因为国内政局动荡、加上美国升息，和穆迪可能下调国家信贷评级，今年至今，土耳其里拉兑美元和兑令吉，分别贬值了20%和21%。
IHH医疗保健集团（IHH，5225，主板贸服股）持有Acibadem控股60%股权，该集团在土耳其、中欧和东欧、中东及南非有医院。
目前，Acibadem控股因为融资成本高，且有外汇亏损，入账IHH的净亏损达9950万令吉。
行家建议：
我们的敏感度测试显示，IHH的营运货币每波动10%，将冲击2018财年股东权益0.2%，和净利7%。而Acibadem控股的债务利率每变化25个基点，将冲击IHH的2018财年净利1.8%。
我们相信IHH会采取行动来消除外汇冲击，包括在土耳其的大选后，重组以美元和欧元为主的债务来降低融资成本和外汇波动。
同时，仍关注收购印度富通医疗集团（Fortis Healthcare）的消息。因为该项收购计划能让IHH进一步拓展印度的版图。
http://www.enanyang.my/news/20180618/ihh医疗保健-须消除外汇冲击/
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
Market Buzz
2025-01-14
IHH2025-01-14
IHH2025-01-13
IHH2025-01-13
IHH2025-01-10
IHH2025-01-10
IHH2025-01-10
IHH2025-01-10
IHH2025-01-10
IHH2025-01-09
IHH2025-01-09
IHH2025-01-09
IHH2025-01-09
IHH2025-01-08
IHH2025-01-08
IHH2025-01-08
IHH2025-01-08
IHH2025-01-08
IHH
2025-01-07
IHH2025-01-07
IHH2025-01-07
IHH2025-01-07
IHHMore articles on 南洋行家论股
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2025-01-16 12:30:00
EMA 5
30 Mins
BUY
2025-01-16 12:20:00
VOLUME BREAKOUT
10 Mins
BUY
2025-01-16 12:20:00
TURTLE SYSTEM 20
10 Mins
BUY
2025-01-16 11:30:00
ADX
10 Mins
BUY
2025-01-16 11:20:00
EMA 5
10 Mins
BUY
Apps
Top Articles
1
2
3
RHB Investment Research Reports
4
Good Articles to Share
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing (Correct)
5
Good Articles to Share
Evercore ISI's Julian Emanuel says its too early to buy weakness
6
Good Articles to Share
7
Good Articles to Share
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
